FDA Approves IND for Phase 3 Trial of iSCIB1+ in Melanoma

from TheBrief.Health · host TheBrief.Health

FDA approval of a phase 3 trial for the iSCIB1+ melanoma vaccine advances personalized cancer treatment, offering potential survival benefits for patients with advanced disease.

Episode metadata supplied by the publisher feed · Published Jun 3, 2026

Embed this episode

Attribution link and audio player

NOW PLAYING

FDA Approves IND for Phase 3 Trial of iSCIB1+ in Melanoma

0:00 1:24

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of TheBrief.Health?

This episode is 1 minute long.

When was this TheBrief.Health episode published?

This episode was published on June 3, 2026.

Can I download this TheBrief.Health episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!